Results 31 to 40 of about 5,671 (151)

Abiraterone Acetate and Castration Resistant Ductal Adenocarcinoma of the Prostate

open access: yesCase Reports in Urology, 2014
Ductal adenocarcinoma of the prostate is a rare histological variant that only represents
Edgar Linden-Castro   +5 more
doaj   +1 more source

Prostate Cancer Patient‐Derived Organoids (PDOs) as Functional Avatars for Antisense Oligonucleotide (ASO)‐Based Personalized Therapy

open access: yesAdvanced Healthcare Materials, Volume 15, Issue 41, 6 November 2026.
Prostate patient‐derived organoids (PDOs) were established from TURP and biopsy specimens with >90% success and retain key features of their tissues of origin, making them functional avatars for antisense oligonucleotide (ASO) therapy . Transfecting single cells outside the Matrigel matrix and then reconstituting organoids overcomes the 3D delivery ...
Thi Thom Tran   +15 more
wiley   +1 more source

Serious Hypokalemia Associated with Abiraterone Acetate in Patients with Castration-Resistant Prostate Cancer

open access: yesCase Reports in Urology, 2018
Introduction. The treatment strategy for castration-resistant prostate cancer (CRPC) has changed with the approval of several new agents. In 2011, abiraterone acetate was approved for the treatment of metastatic CRPC; however abiraterone is known to ...
Yutaka Yamamoto   +7 more
doaj   +1 more source

Abiraterone Acetate Withdrawal Syndrome: Does It Exist

open access: yesCase Reports in Oncology, 2012
In 2011 abiraterone acetate (AA) was approved for the treatment of castrate-resistant metastatic prostate cancer patients who have failed docetaxel chemotherapy.
Hélène Gauthier   +3 more
doaj   +1 more source

Prostatic Adenosquamous Carcinoma With a Minute Squamous Component in the Initial Biopsy and Early Liver Metastasis: A Case Report

open access: yesIJU Case Reports, Volume 9, Issue 6, November 2026.
ABSTRACT Introduction We report a case of de novo prostatic adenosquamous carcinoma with a minute squamous component in the initial biopsy and early liver metastasis despite a marked prostate‐specific antigen response. Case Presentation A 72‐year‐old man was diagnosed with locally advanced prostate cancer with nodal and multiple bone metastases ...
Yohei Tsubouchi   +9 more
wiley   +1 more source

Abiraterone in the management of castration-resistant prostate cancer prior to chemotherapy

open access: yesTherapeutic Advances in Urology, 2015
The treatment armamentarium for metastatic castration-resistant prostate cancer (mCRPC) has increased significantly over the past several years. Approved drugs associated with improved survival include androgen pathway-targeted agents (abiraterone ...
Benjamin A. Gartrell, Fred Saad
doaj   +1 more source

Investigating the Anti-Tubercular Potential of Novel Non-Antibiotic Agents against Drug-Resistant Mycobacterium Tuberculosis

open access: yesBioscientific Review
Background. The ever-increasing prevalence of multidrug-resistant Mycobacterium tuberculosis (MDR-TB) presents an alarming challenge to existing tuberculosis (TB) treatment stratgies.
Muhammad Fayaz Khan   +6 more
doaj   +1 more source

Longitudinally Monitoring Prostate Cancer Bone Metastasis and Treatment Response via Circulating Extracellular Vesicles

open access: yesJournal of Extracellular Vesicles, Volume 15, Issue 10, October 2026.
ABSTRACT Lethal prostate cancer (PCa) is dominated by treatment‐refractory progression in bone. In this study, we used plasma‐derived extracellular vesicles (EVs) for monitoring the tumour and therapy‐induced changes in the bone tumour microenvironment (bone‐TME) in men with bone metastatic PCa (M1b PCa).
Emanuela Gentile   +11 more
wiley   +1 more source

A phase 3, double-blind, randomized placebo-controlled efficacy and safety study of abiraterone acetate in chemotherapy-naïve patients with mCRPC in China, Malaysia, Thailand and Russia

open access: yesAsian Journal of Urology, 2017
Objective: This double-blind, placebo-controlled phase 3 study was designed to compare efficacy and safety of abiraterone acetate + prednisone (abiraterone) to prednisone alone in chemotherapy-naïve, asymptomatic or mildly symptomatic metastatic ...
Dingwei Ye   +16 more
doaj   +1 more source

Ineffectiveness of immune checkpoint inhibitors in prostate cancer: is it just a question of ‘‐mabs’?

open access: yesThe Journal of Pathology, Volume 270, Issue 2, Page 139-162, October 2026.
Abstract Prostate cancer (PCa) is the second most common type of neoplasm, currently treated with a variety of therapeutic agents. Although advances in treatment over the past decade have improved overall survival, patients with advanced PCa eventually progress from hormone‐sensitive PCa to metastatic castration‐resistant PCa.
Giuseppe Schepisi   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy